<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

1 min read

AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity

AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity

Program launches with fixed price and 1.0KG of product in 11 months for monoclonal antibody projects

AGCellerate on display at BIO International conference in Boston June 5-8

Today we announced AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers. AGCellerate offers guaranteed amounts at fixed timelines and costs –accelerating projects through development and into clinical phases.

The new program offers support to biologics projects using monoclonal antibodies (mAbs), lentiviral vectors, adeno-associated vectors and Plasmid DNA (pDNA) material. The AGCellerate mAb program is immediately available, and the company plans to release details on the other modalities later this year.

AGCellerate for mAbs

The AGCellerate mAb program offers 1.0 KG of clinical ready drug substance in 11 months. This delivers the quantity needed, in a fast timeline and at a fixed price to support strategic early phase goals, helping developers reach the clinic as quickly as possible.

AGCellerate for mAbs is supported by AGC Biologics’ proprietary Chef-1™ platform, an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved cell line used in four commercial products and 54 molecules at various stages of clinical development.

Drawing on 30 years of scientific expertise, the AGCellerate program offers a templated approach to maximize speed and product deliverables. It is backed by AGC Biologics' quality services committed to producing GMP compliant biopharmaceuticals, and a global supply chain network to help projects start quickly and remain on time.

“There is one overarching goal for our partners – to create something that will positively affect patients and families seeking life changing treatments. That is at the center of everything we strive to do at AGC Biologics.” said JB Agnus, Chief Business Officer, AGC Biologics. “AGCellerate is designed to help achieve these patient-focused milestones by offering reliable, standardized drug production without surprises.”

AGC Biologics is featuring the new AGCellerate platform for mAbs at BIO International in Boston this week, June 5-8, at booth #3365 - 3369 in the Contract Services Zone. Visit their official website to learn more about the company’s presence at the show.

To access more details about AGCellerate and how it can accelerate projects from bench to clinic, visit www.agcbio.com/capabilities/agcellerate-dna-to-ind-drug-substance-cdmo-services.